Although immune checkpoint-based therapy has marked a milestone in advanced lung cancer, only 30% of patients respond favorably to monotherapy with immune checkpoint inhibitors (ICIs) against programmed cell death ligand 1 (PD-L1) [1]. Here, CD274 is linked to lung cancer.